PnuVax | Blogspot: April 2019

Based in Kingston, Canada, PnuVax and its experienced team of scientists and administrators are committed to promoting public health around the globe. Over the years, the company principals has spearheaded the production of numerous preventative vaccines and biopharmaceutical medications. PnuVax’s most recent accomplishments include securing a $29.4 million grant to develop and test an innovative new pneumococcal conjugate vaccine. In an attempt to curb the scourge of pneumonia, which is the leading cause of death worldwide for children under age 5, this PnuVax vaccine combats multiple variations of the pneumococcus bacterium.

Other recent PnuVax initiatives include an inactivated yellow fever vaccine that serves as a viable alternative to the live-virus yellow fever vaccine that can lead to critical side effects in the elderly, individuals with severe immune system deficiencies, individuals with serious egg allergies, and other vulnerable populations. PnuVax began developing this vaccine in conjunction with GE Healthcare after acquiring a Life Sciences FlexFactory from the company in 2016.

PnuVax | Blogspot

Wednesday, April 10, 2019

CBB Guest Seminar - Dr. Donald Gerson; PnuVax: "A Wide-Angle View of Vac...